KRYSTEXXA (also known as Pegloticase)
Mechanism:
Krystexxa is an enzyme that breaks down uric acid, which otherwise accumulates in gout and precipitates, causing gout flares.
Indications:
Contraindications:
Patients with G6PD deficiency should not be started on Krystexxa. Patients with heart failure should consult their physicians before starting on Krystexxa.
Administration:
Krystexxa is typically administered as an infusion every 2 weeks.